Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBIT (2020 - 2025)

Tarsus Pharmaceuticals has reported EBIT over the past 6 years, most recently at -$8.0 million for Q4 2025.

  • Quarterly results put EBIT at -$8.0 million for Q4 2025, up 67.34% from a year ago — trailing twelve months through Dec 2025 was -$71.0 million (up 41.14% YoY), and the annual figure for FY2025 was -$71.0 million, up 41.14%.
  • EBIT for Q4 2025 was -$8.0 million at Tarsus Pharmaceuticals, up from -$14.5 million in the prior quarter.
  • Over the last five years, EBIT for TARS hit a ceiling of $10.7 million in Q1 2021 and a floor of -$44.4 million in Q4 2023.
  • Median EBIT over the past 5 years was -$22.5 million (2022), compared with a mean of -$20.5 million.
  • Biggest five-year swings in EBIT: skyrocketed 605.85% in 2021 and later tumbled 528.27% in 2023.
  • Tarsus Pharmaceuticals' EBIT stood at -$14.4 million in 2021, then decreased by 4.24% to -$15.1 million in 2022, then plummeted by 195.13% to -$44.4 million in 2023, then soared by 45.06% to -$24.4 million in 2024, then skyrocketed by 67.34% to -$8.0 million in 2025.
  • The last three reported values for EBIT were -$8.0 million (Q4 2025), -$14.5 million (Q3 2025), and -$22.2 million (Q2 2025) per Business Quant data.